BARCELONA — In this video perspective from the International Liver Congress, Fred Poordad, MD, discusses the combination treatment of ABT-493 and ABT-530 (AbbVie) for patients who previously failed direct-acting antiviral therapies.
“These two next generation agents are truly potent pan-genotypic and for many of the commonly occurring resistant variants we know, they do not appear to hinder the effectiveness of these two drugs,” Poordad told HCV Next.
In the MAGELLAN-1 study, Poordad and colleagues looked at 50 patients with genotype 1 HCV, but without cirrhosis, who had virologic breakthrough on previous DAA therapies. A variety of previous therapies, including two-, three- and four-drug combinations, were experienced by the patients, producing a variety of resistance-associated variants (RAVs).
Sustained virologic response was seen in 100% of patients treated with 200 mg ABT-493 and 80 mg of ABT-530 (n = 6), 91% of those treated with 300 mg ABT-493, 120 mg of ABT-530 in combination with ribavirin (n = 20 of 22) and 86% of those treated with the larger doses without ribavirin (n = 19 of 22).
When looking at RAVs, 100% of those with only NS3 RAVs reached SVR12, 90% of those with only NS5A RAVs and 94% of those with both. Poordad also reported that 92% of patients with two or more RAVs reached SVR12.
“For many of the failures we see currently, we will have an answer for these individuals when this regimen comes to market hopefully in the future,” Poordad said.
Disclosure: Poordad reports financial relationships with AbbVie, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Biolex Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead Sciences, GlaxoSmithKline, GlobeImmune, Idenix Pharmaceuticals, Idera Pharmaceuticals, Intercept Pharmaceuticals, Janssen, Kadmon, Medarex, Medtronic, Merck, Novartis, Onyx/Bayer, Santaris Pharmaceuticals, Salix, Scynexis Pharmaceuticals, Tibotec/Janssen, Vertex Pharmaceuticals and ZymoGenetics.